Clinical trials: Japanese Encephalitis Vaccine
Japanese Encephalitis
Safety and Immunogenicity of JECEVAX in Young Children
A dose escalating study with 3 different dosing regimens of the studied vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the…
- Trial name
- NCT02816554
- Testing
- JEVAX, JECEVAX-1, JECEVAX-0.8
- Where
- 2 sites in Vietnam
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- National Institute of Hygiene and Epidemiology, Vietnam
Tick-Borne Encephalitis
Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Tick-Borne Encephalitis (TBE) Vaccine in Healthy Japanese Participants 1 Year of Age and Older
The main purpose of this study is to provide safety and immunogenicity data in Japanese participants.
- Trial name
- NCT04648241
- Testing
- TBE vaccine 0.5 mL, TBE vaccine 0.25 mL
- Where
- 6 sites in Japan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Pfizer
Japanese Encephalitis
Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine
To facilitate introduction of live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) into the National Immunization Programme of Sri Lanka, we evaluated the safety and immunogenicity of co-administration of LJEV and…
- Trial name
- NCT00463476
- Testing
- Live, Attenuated Japanese Encephalitis SA 14-14-2 Vaccine (LJEV)
- Where
- 3 sites in Sri Lanka
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- PATH
Japanese Encephalitis, Hepatitis A
Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children
Safety: To describe the safety profiles following vaccination. Immunogenicity: To describe the immune response after a single dose of vaccine.
- Trial name
- NCT00621764
- Testing
- Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28), Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)
- Where
- 3 sites in Thailand
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
The objective is to assess immunogenicity of a commercial IC51 batch at 3 different time points post filling (12, 18, 24 months) in terms of Geometric Mean Titers (GMT) for anti-JEV neutralizing antibodies at Day 56 after the…
- Trial name
- NCT00776230
- Testing
- IC51
- Where
- 3 sites in Austria, Germany
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Japanese Encephalitis
Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam
A study of the study vaccine (JECEVAX- VABIOTECH-Vietnam) and a licensed vaccine (JEVAX-VABIOTECH-Vietnam) is conducted in Vietnamese children, aged 9 to 24 months to assess the safety of the study vaccine compares to licenced…
- Trial name
- JECEVAX-3 (NCT03282370)
- Testing
- JEVAX, JECEVAX
- Where
- 4 sites in Vietnam
- Volunteers
- 655 people, healthy volunteers welcome
- Sponsor
- National Institute of Hygiene and Epidemiology, Vietnam
Iron Deficiency Anemia
Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine Immunogenicity
Iron deficiency (ID) anaemia (IDA) is a global public health problem, with the highest prevalence in Africa and in South-East Asia.
- Trial name
- NCT06027801
- Testing
- Iron-fortified cookies, Japanese encephalitis (JE) vaccine, Typhoid Vi polysaccharide (Vi-PS) vaccine
- Where
- Thailand
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Japanese Encephalitis
Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51
The objective is to demonstrate equivalence of three IC51 batches in terms of Geometric Mean Titers for anti-JEV neutralizing antibody.
- Trial name
- NCT00594958
- Testing
- IC51
- Volunteers
- 639 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Rabies, Japanese Encephalitis
Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects
Establish non-inferiority of the immune response and evaluate the safety and tolerability of Rabies and Japanese Encephalitis (JE) vaccines given concomitantly or alone and according to either of 2 schedules for preexposure…
- Trial name
- NCT01662440
- Testing
- Rabies, Japanese Encephalitis
- Where
- 3 sites in Austria, Germany and 1 more
- Volunteers
- 661 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Encephalitis, Japanese
Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose
This study aims to understand the persistence of the Japanese encephalitis (JE) antibody response in previously vaccinated children.
- Trial name
- NCT02514746
- Testing
- Live Attenuated Japanese Encephalitis SA-14-14-2 Vaccine
- Volunteers
- 561 people, healthy volunteers welcome
- Sponsor
- PATH
Japanese Encephalitis
Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj
A multi-center, open, phase 4 clinical trial to assess the long-term immunogenicity and safety of fourth administration of Boryung Cell-Culture Japanese Encephalitis Vaccine inj.
- Trial name
- BR-JELITE (NCT02532569)
- Testing
- Japanese encephalitis vaccine
- Where
- 9 sites in South Korea
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Infectious Disease, Yellow Fever
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
We hypothesize that a high CD4+ and CD8+ T cell count will reduce viremia upon challenge with a structurally heterologous virus, and correspondingly result in reduced magnitude of host response to challenge infection.
- Conditions
- Infectious Disease, Yellow Fever, Japanese Encephalitis, Viral Infection
- Trial name
- NCT05568953
- Testing
- Stamaril, Imojev, Ixiaro
- Where
- Singapore
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Japanese Encephalitis, Varicella
Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV
The aim of the study is to investigate the memory immune response and the yearly persistence of the immunity against Japanese Encephalitis (JE) after vaccination with Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in…
- Trial name
- NCT01190228
- Testing
- JE-CV Vaccine, Varicella Vaccine
- Where
- Philippines
- Volunteers
- 454 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Japanese Encephalitis
Postmarketing Surveillance Study for IMOJEV® in Republic of Korea
The purpose of the study is to perform the re-examination of IMOJEV® in routine clinical settings in accordance with the Ministry of Food and Drug Safety regulation.
- Trial name
- NCT02933710
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Encephalitis, Japanese Encephalitis
Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis.
The purpose of this study is to assess whether ChimeriVax™ JE vaccine (a new vaccine to be used for vaccination against Japanese encephalitis) is safe and well tolerated when compared to placebo (dummy) vaccination.
- Trial name
- NCT00314132
- Testing
- ChimeriVax-JE, Japanese Encephalitis vaccine, 0.9% Saline
- Where
- 22 sites in United States, Australia
- Volunteers
- 2,004 people, healthy volunteers welcome
- Sponsor
- Sanofi
Japanese Encephalitis
Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects
The purpose of this study is to describe the immunogenicity and safety of IMOJEV® in adult and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity, reactogenicity, and safety data obtained with…
- Trial name
- NCT02492165
- Testing
- Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)
- Where
- Vietnam
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company